Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties

Left unaddressed, non-alcoholic fatty liver disease (NAFLD) will continue to have substantial health, economic and social implications. To address the challenge, a paradigm shift is needed in the way NAFLD is conceptualised. Concerted, collaborative action across medical specialities, industry sectors and governments will be vital in tackling this public health threat. To drive this change, in this review, we present data on the current global healthcare and socioeconomic costs of NAFLD and highlight priority actions. The estimated healthcare costs of patients with NAFLD are nearly twice as high as their age-matched counterparts without the disease and are highest in those with advanced fibrosis and end-stage liver disease. NAFLD is accountable for the highest increase in DALYs (disability-adjusted life years) among all liver diseases globally. NAFLD and non-alcoholic steatohepatitis (NASH)-specific drug therapies are not yet available and there is considerable uncertainty regarding cost, optimal length of treatment, and their impact on liver-related outcomes and mortality. Among the currently available bariatric procedures, sleeve gastrectomy is reported to be the most cost-effective for NASH resolution. Gastric bypass remains very expensive, while data on bariatric endoscopy are limited. Lastly, we propose a global NAFLD/NASH investment framework to guide the development of achievable yet ambitious country-specific targets and strategic actions to optimise resource allocation and reduce the prevalence of NAFLD and NASH. Its focus on high-level inputs will be critical to enabling a political and financial environment that supports clinical-level implementation of NAFLD prevention, treatment and care efforts, across all settings. & COPY; 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Automated summary

Non-alcoholic fatty liver disease (NAFLD) has significant health, economic and social implications, requiring a shift in conceptualization and collaborative action to address the public health threat. The healthcare costs of NAFLD patients are nearly double compared to those without the disease, with the highest costs in advanced fibrosis and end-stage liver disease. NAFLD accounts for the highest increase in disability-adjusted life years (DALYs) among all liver diseases globally. Currently, there are no specific drug therapies for NAFLD and non-alcoholic steatohepatitis (NASH), with uncertainties surrounding cost, treatment duration, and their impact on liver-related outcomes and mortality.